Industry News
Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib)…
Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–May 24, 2022– DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is sponsoring The Sun Bus, a community service provided by the Colorado Melanoma Foundation in partnership with Epiphany Dermatology, to…
Read More
Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule Excerpt from the Press Release: SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters…
Read More
– Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma – Excerpt from the Press Release: ROTTERDAM, Netherlands and NEWTON, Mass., May 25, 2022 /PRNewswire/ — The European Myeloma Network (EMN), an international collaborative network of expertise centers for…
Read More
Automated and Easily Scalable Swab-Based Workflow Supports Increased Sample Throughput and Processing Consistency Excerpt from the Press Release: WALTHAM, Mass. & WATERTOWN, Mass.–(BUSINESS WIRE)–Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection. The test, based on…
Read More
Expanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 trial of FT-7051 in mCRPC proceeding with predicted efficacious dose range under evaluation and exploring alternative dosing schedule FT-3171 (USP1 inhibitor) introduced targeting BRCA mutant tumors with investigational new drug…
Read More
Long COVID Trial Topline data expected in early Q3 2022 NASH Trial interim data expected in late Q3 2022 OHE Trial Suspended Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that…
Read More
Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor of TGFβ signaling Excerpt from the Press Release: SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) — Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with…
Read More
– EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a…
Read More
– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its…
Read More